#Deafness

The agency's decision is based on results from a clinical trial in which the treatment improved hearing in 80 percent of the pediatric participants. However, Deaf community advocates worry about the push to cure hearing loss

The treatment, developed by Regeneron Pharmaceuticals, is for a very rare form of deafness. But it represents a medical milestone.

Researchers say a gene therapy allowed deaf children and adults as old as 32 to hear for the first time. The benefits have persisted for more than two years for some patients.